News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medtronic Limited (MDT) Completes Enrollment in Global Head-to-Head Stent-Safety Study


2/2/2009 10:40:07 AM

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today announced the completion of enrollment in PROTECT,1 the company’s global study comparing its Endeavor drug-eluting stent (DES) to Johnson & Johnson’s Cypher® DES. A landmark study of groundbreaking devices used to treat coronary artery disease, PROTECT is the first and largest randomized controlled trial (RCT) of its kind.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES